Sirui Li

Sirui Li

Auto-generated profile, based on publicly available information

Sirui Li

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Nature
Verified
Journal Article
Closed access
PDF file
SLSirui Li
Sirui Li
BMBhalchandra Mirlekar
Bhalchandra Mirlekar
BJBrandon M. Johnson
Brandon M. Johnson
WBW. June Brickey
W. June Brickey
JWJohn A. Wrobel
John A. Wrobel
JTJenny P.-Y. Ting
Jenny P.-Y. Ting

27 October 2022 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
Kaiting YangKaiting Yang
Kaiting Yang
WHWenbo Han
Wenbo Han
XJXiaomin Jiang
Xiaomin Jiang
APAndras Piffko
Andras Piffko
JBJason Bugno
Jason Bugno
RWRalph Weichselbaum
Ralph Weichselbaum

13 March 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
YWYing Wang
Ying Wang
SLSirui Li
Sirui Li
MHMengying Hu
Mengying Hu
Yuchen YangYuchen Yang
Yuchen Yang
EMEllie McCabe
Ellie McCabe
RLRihe Liu
Rihe Liu

15 April 2024 in Medical Review
Verified
Journal Article
Open access
PDF file
ZZZheqi Zhou
Zheqi Zhou
SHSanling Huang
Sanling Huang
FFFangying Fan
Fangying Fan
YXYan Xu
Yan Xu
CMCasey Moore
Casey Moore
CHChuanhui Han
Chuanhui Han
As a key sensor of double-stranded DNA (dsDNA), cyclic GMP-AMP synthase (cGAS) detects cytosolic dsDNA and initiates the synthesis of 2′3′ cyclic GMP-AMP (cGAMP) that activates the stimulator of interferon genes (STING). This finally promotes the production of type I interferons (IFN-I) that is crucial for bridging innate and adaptive immunity. Recent evidence show that several antitumor therapies, including radiotherapy (RT), chemotherapy, targeted therapies and immunotherapies, activate the cGAS-STING pathway to provoke the antitumor immunity. In the last decade, the development of STING agonists has been a major focus in both basic research and the pharmaceutical industry. However, up to now, none of STING agonists have been approved for clinical use. Considering the broad expression of STING in whole body and the direct lethal effect of STING agonists on immune cells in the draining lymph node (dLN), research on the optimal way to activate STING in tumor microenvironment (TME) appears to be a promising direction. Moreover, besides enhancing IFN-I signaling, the cGAS-STING pathway also plays roles in senescence, autophagy, apoptosis, mitotic arrest, and DNA repair, contributing to tumor development and metastasis. In this review, we summarize the recent advances on cGAS-STING pathway’s response to antitumor therapies and the strategies involving this pathway for tumor treatment.

5 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WBW. June Brickey
W. June Brickey
DCDavid L. Caudell
David L. Caudell
MAMacintyre Andrew
Macintyre Andrew
JOJohn D. Olson
John D. Olson
YDYanwan Dai
Yanwan Dai
JTJenny P. Y. Ting
Jenny P. Y. Ting
Thrombocytopenia, hemorrhage, anemia, and infection are life-threatening issues following accidental or intentional radiation exposure. Since few therapeutics are available, safe and efficacious small molecules to mitigate radiation-induced injury need to be developed. Our previous study showed the synthetic TLR2/TLR6 ligand fibroblast stimulating lipopeptide (FSL-1) prolonged survival and provided MyD88-dependent mitigation of hematopoietic acute radiation syndrome (H-ARS) in mice. Although mice and humans differ in TLR number, expression, and function, nonhuman primate (NHP) TLRs are like those of humans; therefore, studying both animal models is critical for drug development. The objectives of this study were to determine the efficacy of FSL-1 on hematopoietic recovery in small and large animal models subjected to sublethal total body irradiation and investigate its mechanism of action. In mice, we demonstrate a lack of adverse effects, an easy route of delivery (subcutaneous) and efficacy in promoting hematopoietic progenitor cell proliferation by FSL-1. NHP given radiation, followed a day later with a single subcutaneous administration of FSL-1, displayed no adversity but showed elevated hematopoietic cells. Our analyses revealed that FSL-1 promoted red blood cell development and induced soluble effectors following radiation exposure. Cytologic analysis of bone marrow aspirates revealed a striking enhancement of mononuclear progenitor cells in FSL-1-treated NHP. Combining the efficacy of FSL-1 in promoting hematopoietic cell recovery with the lack of adverse effects induced by a single administration supports the application of FSL-1 as a viable countermeasure against H-ARS.

8 May 2024 in Medical Review
Verified
Journal Article
Open access
PDF file
XLXinliang Lu
Xinliang Lu
XLXiaobing Li
Xiaobing Li
LLLili Li
Lili Li
CHChuanhui Han
Chuanhui Han
SLSirui Li
Sirui Li
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an evolving DNA-sensing mechanism involved in innate immunity and pathogen defense that has been optimized while remaining conserved. Aside from recognizing pathogens through conserved motifs, these receptors also detect aberrant or misplaced self-molecules as possible signs of perturbed homeostasis. Upon binding external or self-derived DNA, a mobile secondary messenger 2′3′-cyclic GMP-AMP (cGAMP) is produced by cGAS and in turn activates its adapter STING in the endoplasmic reticulum (ER). Resting-state or activated STING protein is finely restricted by multiple degradation machineries. The post-translational changes of the STING protein, along with the regulatory machinery of the secret routes, limit the onset, strength and sustention of STING signal. STING experiences a conformational shift and relocates with TBK1 from the ER to perinuclear vesicles containing transcription factors, provoking the transcription activity of IRF3/IFN-I and NF-κB pathways, as well as to initiate a number of cellular processes that have been shown to alter the immune landscape in cancer, such as autophagy, NLRP3 inflammasome, ER stress, and cell death. STING signal thus serves as a potent activator for immune mobilization yet also triggers immune-mediated pathology in tissues. Recent advances have established the vital role of STING in immune surveillance as well as tumorigenic process. This review provides an overview of the disparate outcomes of cancer attributed to the actions of pleiotropic and coordinated STING downstream signalosomes, along with the underlying mechanisms of STING function in pathologies, providing therapeutic implications for new approaches in hunt for the next generation of cancer immunotherapy base on STING.